Dr. Lucia Gemma Delogu, has worked as Assistant Professor at the University of Sassari 2012-2017, where she has been leading the Laboratory of Bionanotechnology (http://lgdelogulab.uniss.it/). She was visting professor at the Technische Universitat Dresden in Germany (2016-2017). She has worked as: postdoctoral fellow at the University of Southern California, Los Angeles (2007-2009), visiting researcher at the Sanford-Burnham Institute of San Diego (2008) and at the Department of Health and Human Services at the NIH in Bethesda, MD (2013). She is currently coordinating two European Projects: G-IMMUNOMICS (Flagera 2015) and Carbo-IMMAP (RISE HORIZON 2020).
Today, Dr. Delogu’s laboratory focus on the study of nanomaterials in the biomedicine scenario, with a particular emphasis on i) their interactions with the immune system, ii) their potential use as contrast agents, iii) their application in space biology.
The Department of Chemical and Pharmaceutical Sciences is comprised of a group of scientists with strong expertise in Biochemistry, Pharmacology and nanotechnology, providing an invaluable pool of know-how for the development of new nanoproducts and therapies. The Dr. Delogu’s Bionanotechnology Group is one of the world leading group operating in the field of the immune-phenotyping of carbon nanomaterials, with a well renowned expertise in the evaluation of the immune-biocompatibility of Carbon based materials.
Available equipment and techniques:
The Department is equipped with infrastructures for performing top research, including state-of-the-art instruments. Available facilities relevant to this project includes: 1) a flow cytometry facility with a FACS Canto BD biosciences and a FACS Calibur BD biosciences, as well as a Data analysis station provided with DIVA, Cytospade and FlowJo software. 2) A fully equipped cell culture facility. The laboratory has access to cutting edge instruments i.e. Electronic and Confocal Microscopy and Omics Sciences (Metabolomics and proteomics), Mass spectrometry and Gas chromatography and the CYTOF 2 technology.